| Edward Capoccia, MD | |
|
4320 Fir St Unit 220, East Chicago, IN 46312-3076 | |
| (219) 703-2591 | |
| Not Available |
| Full Name | Edward Capoccia |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 9 Years |
| Location | 4320 Fir St Unit 220, East Chicago, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891177051 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 125067811 (Illinois) | Secondary |
| 208800000X | Urology | 036152414 (Illinois) | Secondary |
| 208800000X | Urology | 01085981A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Hospital | Munster, IN | Hospital |
| St Catherine Hospital Inc | East chicago, IN | Hospital |
| Central Dupage Hospital | Winfield, IL | Hospital |
| St Mary Medical Center Inc | Hobart, IN | Hospital |
| Franciscan Health Dyer | Dyer, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Care Network Inc | 3678737012 | 360 |
| Uro Surgery Associates Llc | 8628975562 | 12 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
Reports show that most Australians are complacent about getting AIDS. They feel that unless a person is homosexual or an injecting drug user or a sex worker, they are not at risk.
Brazilian textile companies have begun producing and marketing fabrics treated with silver and silica nanoparticles developed by the research groups at the Centre for Functional Materials (CDMF) and the Theoretical and Computational Chemistry Laboratory (QTC) at the Universitat Jaume I, in collaboration with the company Nanox Tecnologia, which provide the new fabrics with antibacterial, antifungal and antiviral properties with 99.99% effectiveness.
Bacteria that cause the bubonic plague may be more virulent than their close relatives because of a single genetic mutation, according to research published in the May issue of the journal Microbiology.
› Verified 6 days ago
| Entity Name | Uro Surgery Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648566 PECOS PAC ID: 8628975562 Enrollment ID: O20031217000998 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
Reports show that most Australians are complacent about getting AIDS. They feel that unless a person is homosexual or an injecting drug user or a sex worker, they are not at risk.
Brazilian textile companies have begun producing and marketing fabrics treated with silver and silica nanoparticles developed by the research groups at the Centre for Functional Materials (CDMF) and the Theoretical and Computational Chemistry Laboratory (QTC) at the Universitat Jaume I, in collaboration with the company Nanox Tecnologia, which provide the new fabrics with antibacterial, antifungal and antiviral properties with 99.99% effectiveness.
Bacteria that cause the bubonic plague may be more virulent than their close relatives because of a single genetic mutation, according to research published in the May issue of the journal Microbiology.
› Verified 6 days ago
| Entity Name | Community Care Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457610487 PECOS PAC ID: 3678737012 Enrollment ID: O20120614000331 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
Reports show that most Australians are complacent about getting AIDS. They feel that unless a person is homosexual or an injecting drug user or a sex worker, they are not at risk.
Brazilian textile companies have begun producing and marketing fabrics treated with silver and silica nanoparticles developed by the research groups at the Centre for Functional Materials (CDMF) and the Theoretical and Computational Chemistry Laboratory (QTC) at the Universitat Jaume I, in collaboration with the company Nanox Tecnologia, which provide the new fabrics with antibacterial, antifungal and antiviral properties with 99.99% effectiveness.
Bacteria that cause the bubonic plague may be more virulent than their close relatives because of a single genetic mutation, according to research published in the May issue of the journal Microbiology.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edward Capoccia, MD 400 W 84th Dr, Merrillville, IN 46410-6248 Ph: () - | Edward Capoccia, MD 4320 Fir St Unit 220, East Chicago, IN 46312-3076 Ph: (219) 703-2591 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.
Reports show that most Australians are complacent about getting AIDS. They feel that unless a person is homosexual or an injecting drug user or a sex worker, they are not at risk.
Brazilian textile companies have begun producing and marketing fabrics treated with silver and silica nanoparticles developed by the research groups at the Centre for Functional Materials (CDMF) and the Theoretical and Computational Chemistry Laboratory (QTC) at the Universitat Jaume I, in collaboration with the company Nanox Tecnologia, which provide the new fabrics with antibacterial, antifungal and antiviral properties with 99.99% effectiveness.
Bacteria that cause the bubonic plague may be more virulent than their close relatives because of a single genetic mutation, according to research published in the May issue of the journal Microbiology.
› Verified 6 days ago
Kevin Parikh, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 4320 Fir St Unit 220, East Chicago, IN 46312 Phone: 219-703-2591 |